Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Income from Continuing Operations: 2022-2025

Historic Income from Continuing Operations for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$892,296.

  • Addex Therapeutics' Income from Continuing Operations rose 44.61% to -$892,296 in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.7 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of -$5.6 million for FY2024, which is 100.46% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Income from Continuing Operations is -$892,296, which was down 37.78% from -$647,610 recorded in Q1 2025.
  • Addex Therapeutics' Income from Continuing Operations' 5-year high stood at $6.6 million during Q4 2022, with a 5-year trough of -$7.5 million in Q2 2022.
  • For the 3-year period, Addex Therapeutics' Income from Continuing Operations averaged around -$1.2 million, with its median value being -$952,337 (2023).
  • In the last 5 years, Addex Therapeutics' Income from Continuing Operations surged by 93.66% in 2023 and then slumped by 119.12% in 2024.
  • Over the past 4 years, Addex Therapeutics' Income from Continuing Operations (Quarterly) stood at $6.6 million in 2022, then plummeted by 115.36% to -$1.0 million in 2023, then tumbled by 34.16% to -$1.4 million in 2024, then surged by 44.61% to -$892,296 in 2025.
  • Its Income from Continuing Operations was -$892,296 in Q2 2025, compared to -$647,610 in Q1 2025 and -$1.4 million in Q4 2024.